Related Experiment Video

Updated: Jun 27, 2026

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting

Jill Wykosky1, Waldemar Debinski

  • 1Department of Neurosurgery, Brain Tumor Center of Excellence, Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

Molecular Cancer Research : MCR
|December 17, 2008
PubMed

Insights

EphA2 and ephrinA1 proteins are key in solid tumor development. Their complex roles in cancer progression offer potential therapeutic targeting opportunities.

Area of Science:

  • Cell Biology
  • Oncology
  • Molecular Biology

Background:

  • Eph receptor tyrosine kinases (RTKs) and ephrin ligands are crucial for development.
  • Emerging evidence highlights their significant roles in cancer formation and progression.
  • EphA2 and ephrinA1 are implicated in the development and maintenance of various solid tumors.

Purpose of the Study:

  • To review the complex roles of EphA2 and ephrinA1 in solid tumor malignancy.
  • To emphasize the impact of cell type and microenvironment on EphA2/ephrinA1 signaling.
  • To explore therapeutic targeting opportunities for EphA2 and ephrinA1 in cancer.

Main Methods:

  • Literature review focusing on EphA2 and ephrinA1 in tumorigenesis.
  • Analysis of how cell type and microenvironment influence EphA2/ephrinA1 expression and signaling.
  • Examination of the functional consequences of EphA2/ephrinA1 signaling on tumor and associated cells.

Main Results:

  • EphA2 and ephrinA1 exhibit complex, context-dependent functions in tumor progression.
  • Signaling pathways and protein expression are modulated by cellular and microenvironmental factors.
  • These proteins influence the behavior of both tumor cells and tumor-associated cells.

Conclusions:

  • EphA2 and ephrinA1 are critical players in solid tumor progression.
  • Understanding their cell-specific functions is key to developing targeted therapies.
  • Targeting EphA2 and ephrinA1 pathways presents promising therapeutic strategies for solid tumors.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...